Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours

What happened

The FDA granted Inovio accelerated approval for VOCERYQ to reduce how often adults with recurrent respiratory papillomatosis need surgery. In the reported study, 7 of 26 patients needed no surgery for 12 months after treatment. Inovio expects orders and shipping in about 60 days; a confirmatory study is planned.

Global impact / market context

The approval gives Inovio a new approved treatment and may reduce surgery for some patients. The evidence is limited: 7 of 26 patients needed no surgery over the stated period, and a follow-up study is planned to confirm the benefit. The supplied reports also describe a sharp rise in Inovio shares, but that does not establish how the market will move next.

What to watch

1. Check whether orders and shipping begin in about 60 days, as Inovio expects; this would show whether supply is starting.
2. Check the planned first-quarter 2027 commercial rollout; its timing matters for how broadly the treatment may become available.
3. Check for results from the planned confirmatory study; they matter because the approval is accelerated and the benefit still needs confirmation.

Affected assets

• Inovio Pharmaceuticals, Inc.
• Precigen, Inc.

Evidence

• Infoway News — INO: VOCERYQ wins FDA approval to reduce surgery frequency in adults with RRP 2026-11-02T14:41:17+00:00
• Infoway News — INO: VOCERYQ gains accelerated approval; 27% had no surgery in the year after treatment 2026-11-02T13:58:48+00:00
• Infoway News — Inovio Wins FDA Accelerated Approval for VOCERYQ to Reduce RRP Surgery 2026-11-02T12:23:00+00:00
• Infoway News — This Healthcare Stock Just Soared 200% 2026-11-02T11:17:02+00:00
• Infoway News — Weekly Recap: First FDA approval and VOCERYQ rollout planned for Q1 2027 2026-11-02T11:00:00+00:00
• Infoway News — PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings 2026-11-02T08:40:18+00:00
• Infoway News — INO: VOCERYQ wins accelerated approval; 7 of 26 patients achieved 12-month complete response 2026-10-30T22:34:45+00:00
• Infoway News — PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval 2026-10-30T22:24:20+00:00
• Infoway News — Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours 2026-10-30T22:23:00+00:00
• Infoway News — INOVIO Pharmaceuticals, Inc. (INO) Wins FDA Accelerated Approval for VOCERYQ in Adult RRP 2026-10-30T22:01:00+00:00
• Infoway News — INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) 2026-10-30T22:01:00+00:00
• Infoway News — Inovio surges 300% following FDA approval of Voceryq for rare disease 2026-10-30T21:35:42+00:00
• Incident timeline — INO: VOCERYQ wins FDA approval to reduce surgery frequency in adults with RRP
• Incident timeline — INO: VOCERYQ gains accelerated approval; 27% had no surgery in the year after treatment
• Incident timeline — Inovio Wins FDA Accelerated Approval for VOCERYQ to Reduce RRP Surgery
• Incident timeline — This Healthcare Stock Just Soared 200%
• Incident timeline — Weekly Recap: First FDA approval and VOCERYQ rollout planned for Q1 2027
• Incident timeline — PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings
• Incident timeline — INO: VOCERYQ wins accelerated approval; 7 of 26 patients achieved 12-month complete response
• Incident timeline — PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval
• Incident timeline — Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours
• Incident timeline — INOVIO Pharmaceuticals, Inc. (INO) Wins FDA Accelerated Approval for VOCERYQ in Adult RRP
• Incident timeline — INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
• Incident timeline — Inovio surges 300% following FDA approval of Voceryq for rare disease